Literature DB >> 25417101

Camouflage and misdirection: the full-on assault of ebola virus disease.

John Misasi1, Nancy J Sullivan2.   

Abstract

Ebolaviruses cause a severe hemorrhagic fever syndrome that is rapidly fatal to humans and nonhuman primates. Ebola protein interactions with host cellular proteins disrupt type I and type II interferon responses, RNAi antiviral responses, antigen presentation, T-cell-dependent B cell responses, humoral antibodies, and cell-mediated immunity. This multifaceted approach to evasion and suppression of innate and adaptive immune responses in their target hosts leads to the severe immune dysregulation and "cytokine storm" that is characteristic of fatal ebolavirus infection. Here, we highlight some of the processes by which Ebola interacts with its mammalian hosts to evade antiviral defenses.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25417101      PMCID: PMC4243531          DOI: 10.1016/j.cell.2014.10.006

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  121 in total

1.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.

Authors:  Z Y Yang; H J Duckers; N J Sullivan; A Sanchez; E G Nabel; G J Nabel
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

2.  Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography.

Authors:  Tanmay A M Bharat; Takeshi Noda; James D Riches; Verena Kraehling; Larissa Kolesnikova; Stephan Becker; Yoshihiro Kawaoka; John A G Briggs
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-27       Impact factor: 11.205

3.  Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.

Authors:  Lisa A Lopez; Su Jung Yang; Heiko Hauser; Colin M Exline; Kevin G Haworth; Jill Oldenburg; Paula M Cannon
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

4.  Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change.

Authors:  Matthew Brecher; Kathryn L Schornberg; Sue E Delos; Marnie L Fusco; Erica Ollmann Saphire; Judith M White
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

5.  Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.

Authors:  Kartik Chandran; Nancy J Sullivan; Ute Felbor; Sean P Whelan; James M Cunningham
Journal:  Science       Date:  2005-04-14       Impact factor: 47.728

6.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

Review 7.  Regulation of type I interferon responses.

Authors:  Lionel B Ivashkiv; Laura T Donlin
Journal:  Nat Rev Immunol       Date:  2014-01       Impact factor: 53.106

8.  Structure of the Ebola VP35 interferon inhibitory domain.

Authors:  Daisy W Leung; Nathaniel D Ginder; D Bruce Fulton; Jay Nix; Christopher F Basler; Richard B Honzatko; Gaya K Amarasinghe
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-02       Impact factor: 11.205

9.  Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR.

Authors:  George Lin; Graham Simmons; Stefan Pöhlmann; Frédéric Baribaud; Houping Ni; George J Leslie; Beth S Haggarty; Paul Bates; Drew Weissman; James A Hoxie; Robert W Doms
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine.

Authors:  Stephanie Jemielity; Jinyize J Wang; Ying Kai Chan; Asim A Ahmed; Wenhui Li; Sheena Monahan; Xia Bu; Michael Farzan; Gordon J Freeman; Dale T Umetsu; Rosemarie H Dekruyff; Hyeryun Choe
Journal:  PLoS Pathog       Date:  2013-03-28       Impact factor: 6.823

View more
  36 in total

1.  Robust and sustained immune activation in human Ebola virus infection.

Authors:  Judith N Mandl; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-07       Impact factor: 11.205

2.  Structural and molecular basis for Ebola virus neutralization by protective human antibodies.

Authors:  John Misasi; Morgan S A Gilman; Masaru Kanekiyo; Miao Gui; Alberto Cagigi; Sabue Mulangu; Davide Corti; Julie E Ledgerwood; Antonio Lanzavecchia; James Cunningham; Jean Jacques Muyembe-Tamfun; Ulrich Baxa; Barney S Graham; Ye Xiang; Nancy J Sullivan; Jason S McLellan
Journal:  Science       Date:  2016-02-25       Impact factor: 47.728

3.  A Sensitive in Vitro High-Throughput Screen To Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface.

Authors:  Gai Liu; Peter J Nash; Britney Johnson; Colette Pietzsch; Ma Xenia G Ilagan; Alexander Bukreyev; Christopher F Basler; Terry L Bowlin; Donald T Moir; Daisy W Leung; Gaya K Amarasinghe
Journal:  ACS Infect Dis       Date:  2017-02-09       Impact factor: 5.084

4.  Ebolavirus evolves in human to minimize the detection by immune cells by accumulating adaptive mutations.

Authors:  Arunachalam Ramaiah; Vaithilingaraja Arumugaswami
Journal:  Virusdisease       Date:  2016-02-22

Review 5.  Clinical Evaluation of Ebola Virus Disease Therapeutics.

Authors:  Guodong Liu; Gary Wong; Shuo Su; Yuhai Bi; Frank Plummer; George F Gao; Gary Kobinger; Xiangguo Qiu
Journal:  Trends Mol Med       Date:  2017-08-17       Impact factor: 11.951

6.  The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.

Authors:  Constantin Brinkmann; Inga Nehlmeier; Kerstin Walendy-Gnirß; Julia Nehls; Mariana González Hernández; Markus Hoffmann; Xiangguo Qiu; Ayato Takada; Michael Schindler; Stefan Pöhlmann
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

7.  Novel Stable Ebola Virus Minigenome Replicon Reveals Remarkable Stability of the Viral Genome.

Authors:  Wanyin Tao; Tianyu Gan; Mingzhe Guo; Yongfen Xu; Jin Zhong
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

Review 8.  Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense.

Authors:  Aryn A Price; Arash Grakoui; David S Weiss
Journal:  Trends Microbiol       Date:  2016-02-03       Impact factor: 17.079

Review 9.  Hunting Viral Receptors Using Haploid Cells.

Authors:  Sirika Pillay; Jan E Carette
Journal:  Annu Rev Virol       Date:  2015-07-02       Impact factor: 10.431

Review 10.  Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead.

Authors:  Everardo González-González; Mario Moisés Alvarez; Alan Roberto Márquez-Ipiña; Grissel Trujillo-de Santiago; Luis Mario Rodríguez-Martínez; Nasim Annabi; Ali Khademhosseini
Journal:  Crit Rev Biotechnol       Date:  2015-11-26       Impact factor: 8.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.